Developing antibodies to target specific cancer mutations
Official title: A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
Funded at Abbratech, INC. · NIH-11077173 · Data updated 2026-11-12
This study is working on new antibodies that can help the immune system better recognize and attack cancer cells with a specific KRAS mutation, aiming to make treatments more effective and safer for patients with these types of cancers.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abbratech, INC. NIH-funded |
| Lab location | 1 site (Branford, UNITED STATES) |
| Project start | July 1, 2023 |
| Project end | January 20, 2025 |
| Funding year | 2025 |
| Award (this year) | $1 |
| NIH project number | 2R44GM149009-02 |
| Project ID | NIH-11077173 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that harbor KRASG12D mutations.
✕Less likely to help
Patients without KRAS mutations or those with cancers not associated with this specific mutation may not benefit from this research.
What this research studies
This research focuses on creating T cell receptor mimic antibodies that specifically target KRAS mutations, particularly the KRASG12D variant. Using innovative technology, the project aims to enhance the effectiveness of immunotherapies by developing antibodies that can differentiate between cancerous and normal cells. This approach seeks to improve treatment precision and reduce side effects for patients with cancers associated with these mutations.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer treatments with fewer side effects.
How similar studies have gone: Similar research approaches have shown promise in targeting specific mutations in cancer therapies, indicating potential for success in this novel application.
Where this research is happening
-
Abbratech, INC.
Branford, United States Active
Researchers
- Principal investigator: Weiner, Michael P — Abbratech, INC.
- Study coordinator: Weiner, Michael P
Related research
Other NIH-funded projects on the same topics.
-
Antibody Platform for Protein Isoform Splice-Junctions
A fast-track NIH grant aims to create antibodies that specifically recognize unique splice-junctions in proteins, helping to better understand and treat diseases linked to alternative splicing.
-
Creating special antibodies to find disease-related protein changes
This project aims to create new tools, called antibodies, that can find specific changes in proteins linked to various diseases, including cancer.
-
Developing antibodies to fight COVID-19 using advanced technology
This study is working on developing special antibodies that can fight the COVID-19 virus, using a new method to make sure they can keep up with any changes the virus might make, which could help improve treatments for COVID-19 and other infections.
-
Developing antibodies to target specific protein splice variants
This study is working on a new way to find and test special antibodies that can help us understand and treat diseases like cancer by focusing on how proteins are made in different forms, which can change how they behave in the body.
-
Validating antibodies for detecting modified proteins
This study is working to make sure that the tools scientists use to find certain proteins in the lab are more accurate and reliable, which will help improve research and treatments for patients.
-
A platform for quickly creating and testing antibodies
This study is working on a new way to quickly create and test special proteins called antibodies that can help treat diseases, so patients can get better treatments faster and more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.